Pharmaceutical intermediates
Lasmiditan Intermediates
1 pharmaceutical intermediate for Lasmiditan. Indication: Migraine.
About Lasmiditan
- Originator
- Eli Lilly
- Indication
- Migraine
- Approved Date
- 12/18/2020
- NCE Patent
- 01/31/2025
- DS/DP
- 02/17/2028
Available intermediates
1 intermediate currently listed for Lasmiditan. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2,4,6-Trifluorobenzoic acid | 28314-80-9 | / | / |
Building toward Lasmiditan?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →